Skip to main content

Management of H.pylori and NSAID-associated ulcers Eradication!

MANAGEMENT FOR H.PYLORI ERADICATION



  • It is known that H.pylori infection is associated with over 90% of duodenal ulcers and 80% of Gastric Ulcers.
  • Antibiotics alone or acid-suppressing agents alone, do not eradicate H.pylori.
  • Both therapies act synergistically as growth of the organism occurs at elevated pH and antibiotics efficacy is enhanced during growth. Additionally, increasing intragastric pH may enhance antibiotic absorption.
  • High eradication rates are achieved by a short course of Triple Therapy consisting of:
           1.PPI                                         2. Clarithromycin                         3. Amoxicillin/Metronidazole
         in a twice recommended simultaneous regimen.


First-Line Therapy: 

European Guidelines recommended 1 week of therapy, whereas the US Guidelines recommend 10-14 days of therapy and achieve 7-9% better eradication rates.
    OCA: Omeprazole(20mg), Clarithromycin (500mg) and Amoxicillin (1g) 
                                                       or
   OCM: Omeprazole (20mg), Clarithromycin (250mg) and Metronidazole (400mg)

  • A lower dose of Clarithromycin (250mg twice daily) is effective and recommended when combined with Metronidazole. (NICE,2004).
  • Omeprazole may be replaced with any of the other PPI drugs.
  • Local resistance rates determine the most appropriate First-line regimens with OCA preferred in areas of high metronidazole resistance.
In the UK, resistance to metronidazole has been reported in about 50% of H.pylori isolates and resistance to Clarithromycin in about 10%. Resistance to Amoxicillin is rare.

  • In patients with hypersensitivity to Penicillin, the OCM regimen or substitution of Amoxicillin from the OCA regimen with Tetracycline 500mg twice daily is used. If patients have recently received antibiotic treatment for any indication, a regimen avoiding that antibiotic is preferred.

Second-Line Therapy:

  • Failure of the first-line regimen to achieve eradication will necessitate treatment with another Triple-Therapy regimen or with a Bismuth-Based Quadruple regimen.
  • Recommended Second-Line therapy regimen include:
              PPI, Amoxicillin or Tetracycline and Metronidazole.

  • Most four-drug regimens contain Bismuth Subsalicylate, Metronidazole, Tetracycline or Amoxicillin and PPI and are generally not well tolerated by patients as Triple-Therapy regimen.

  • Successful eradication relies upon patients adhering to their medication regimen. It is therefore important to educate patients about the principle of eradication therapy and also about coping with common adverse effects associated with their regimen.
  • Diarrhea is the most common adverse effect and should subside after treatment is complete.
  • If eradication is successful, uncomplicated active peptic ulcers heal without the need to continue ulcer-healing drugs beyond the duration of eradication therapy.
  • Patients with persistent symptoms after eradication therapy should have their H.pylori status rechecked.
  • This should be carried out no sooner than 4 weeks after discontinuation of therapy to avoid false-negative results due to suppression rather than eradication of the organism.
  • If the patient is H.pylori positive, an alternate eradication regimen should be given. If eradication was successful but symptoms persist, gastro-esophageal reflux or other causes of dyspepsia should be considered.


MANAGEMENT OF NSAID-ASSOCIATED ULCERS


  • The NSAID-associated ulcers may be H.pylori positive. Eradication is generally recommended in infected patents with NSAID-associated ulcers as it is difficult to differentiate between H.pylori  or NSAID as the cause of the ulcer.
  • If NSAID are discontinued, most uncomplicated ulcers heal using standard doses of a PPI, H-receptor antagonist, Misoprostol or Sucralfate.
  • Healing is impaired if NSAID use is continued.
  • PPIs demonstrate a higher healing rate at 4 weeks but similar healing rates to H2-receptor antagonist at 8 weeks.



Labels:

Comments

Post a Comment

Popular posts from this blog

Diabetes Mellitus: Types!

TYPES OF DIABETES MELLITUS 1. TYPE1 DM Type 1 DM is usually diagnosed before age 30 years, but it can develop at any age. T1DM is an autoimmune disease in which insulin producing B-cells are destroyed. The presence of Human Leucocyte Antigens (HLAs ) is associated with the development of T1DM. In addition, these individuals often develop Islet cell antibodies , Insulin Autoantibodies or Glutamic Acid decarboxylase autoantibodies . At the time of development of diagnosis of T1DM, it is usually believed that most of the patients have 80-90%loss of beta cells. The remaining beta cells function at the diagnosis creates a " HONEYMOON PERIOD" during which the blood glucose levels are easier to control, and smaller amounts of insulin are required. after this, the remaining beta cells function is completely lost, and the patients become completely deficient of insulin and hence require exogenous insulin.  2. TYPE1.5 DM:  Also referred as Latent autoimmune diabetes in Adults (LAD)
Post a Comment
Read more

Diabetes Mellitus: Pharmacotherapy- Gliptins and a-Glycoside Inhibitors!

  PHARMACOTHERAPY:  Medications classifications include:  Sulfonyl Urea's Nonsylfonylurea Secretagogues (a-Glinides) Biguanides Thiazolidinediones a-Glucosidase Inhibitors Dipeptidyl Peptidase-4 Inhibitors (Gliptins) Sodium-glucose co-transporter (SGLT) Inhibitors  Central-Acting Dopamine Agonists Bile Acid Sequestrants Insulin therapy 5. a-GLUCOSIDASE INHIBITORS Acarbose and Miglitol are a-glucosidase inhibitors currently approved in the United States. Mechanism of Action: An enzyme that is along the brush border of the intestine cells called a-glucosidase; breaks down the complex carbohydrates into simple sugars, resulting in absorption. The a-glucosidase inhibitors work by delaying the absorption of carbohydrates from the intestinal tract, which reduces the rise in postprandial glucose levels. Therapy: As a monotherapy , a-glucosidase inhibitors primarily reduce post-prandial glucose excursions.  Clinical Use: FPG concentrations have been decreased by 40-50mg/dL and A1c level
Post a Comment
Read more

GASTRO-ESOPHAGEAL REFLUX DISEASE (GERD)!

MANAGEMENT OF GASTRO-ESOPHAGEAL REFLUX DISEASE  "GERD refers to the endoscopically determined esophagitis or endoscopy-negative reflux disease" . "GERD is the term used to describe any symptomatic clinical condition or histopathological alteration resulting from episodes of reflux of acid, pepsin and occasionally, bile into the esophagus from the stomach". Patients with uninvestigated "reflux-like" symptoms should be managed as patients with uninvestigated dyspepsia. There is currently no evidence that H.pylori should be investigated in patients with GERD. Symptoms: Heartburn is the characteristic symptom of GERD. Acid regurgitation Dysphagia Belching Upper abdominal discomfort Bloating and postprandial fullness Chest pain Hoarseness Cough Complications include: Esophageal ulceration Formation of specialized columnar-lined esophagus at the gastro-esophageal junction known as Barretts Esophagus . Mechanism of Acid Reflux: The mechanism of acid reflux is mu
Post a Comment
Read more